Rallybio Corp — Investor Relations & Filings
Filings indexed
245
across all filing types
Latest filing
2026-05-04
Regulatory Filings
Country
US
United States of America
Listing
US
RLYB
Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | |
| S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | |
| 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 40888387 | 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | ||
| 36271286 | S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | ||
| 32897547 | 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | ||
| 32897544 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | ||
| 32897545 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English | ||
| 32897546 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-20 | English | ||
| 31541794 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31541795 | 8-K Filing | 2026-01-29 | English | ||
| 13111487 | DEF 14A | 2026-01-02 | English | ||
|
2025
6 filings
| |||||
| 13111488 | PRE 14A | 2025-12-23 | English | ||
| 13111490 | 10-Q | 2025-11-06 | English | ||
| 13111494 | 8-K | 2025-11-06 | English | ||
| 13111491 | 8-K | 2025-08-29 | English | ||
| 13111493 | 10-Q | 2025-08-07 | English | ||
| 13111492 | 8-K | 2025-08-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ectin Research AB
Pharmaceutical company developing novel oncology treatments…
|
ECTIN B | SE | Professional, scientific and te… |
|
EdgeLab S.p.A.
Designs and manufactures marine and underwater solutions, i…
|
ELB | IT | Professional, scientific and te… |
|
Editas Medicine, Inc.
A clinical-stage genome editing company developing CRISPR m…
|
EDIT | US | Professional, scientific and te… |
|
EGF Theramed Health Corp.
Developing psychedelic drugs for mental health, diagnostic …
|
TMED | CA | Professional, scientific and te… |
|
Eikon Therapeutics, Inc.
Integrates live-cell imaging and computing to discover ther…
|
EIKN | US | Professional, scientific and te… |
|
Eledon Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for organ and a…
|
ELDN | US | Professional, scientific and te… |
|
Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and …
|
ELIC | SE | Professional, scientific and te… |
|
Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immun…
|
ELTX | US | Professional, scientific and te… |
|
EMYRIA LIMITED
Clinical-stage biotech developing mental health and neurolo…
|
EMD | AU | Professional, scientific and te… |
|
Energenesis Biomedical CO.,LTD.
Develops small molecule drugs for cellular energy regulatio…
|
6657 | TW | Professional, scientific and te… |
Rallybio Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34901/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34901 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34901 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34901 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34901}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Rallybio Corp (id: 34901)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.